Page last updated: 2024-11-10

4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid: RN refers to (E)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

arotinoid acid : A retinoid that consists of benzoic acid substituted at position 4 by a 2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl group. It is a synthetic retinoid that acts as a selective agonist for the retinoic acid receptors (RAR). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5289501
CHEMBL ID275311
CHEBI ID75261
SCHEMBL ID177444
MeSH IDM0116749

Synonyms (109)

Synonym
smr001230750
MLS002153338
bdbm50032219
(e)-4-(2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-enyl)benzoic acid
4-(2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-enyl)benzoic acid
4-[(e)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-benzoic acid
BRD-K49685476-001-02-7
gtpl2646
arotinoid acid
71441-28-6
ro 13-7410
EU-0101176
ccris 3297
agn-191183
agn 191183
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthenyl)-1e-propen-1-yl)benzoic acid
benzoic acid, 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)-, (e)-
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid
p-((e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl)benzoic acid
brn 2008247
lopac-t-3757
tocris-0761
NCGC00016015-01
NCGC00024775-01
4-[(1e)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-enyl]benzoic acid
LOPAC0_001176
SPECTRUM5_001943
BSPBIO_001532
ttnpb
(e)-4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propen-1-yl)benzoic acid
arotinoic acid
1XAP
DB02877
NCGC00024775-06
NCGC00024775-05
NCGC00024775-03
NCGC00024775-07
IDI1_034002
NCGC00024775-08
NCGC00024775-04
NCGC00024775-02
dtxsid6040743 ,
NCGC00016015-03
HMS1989M14
T 3757
NCGC00016015-10
CHEMBL275311 ,
ro-137410
chebi:75261 ,
BML2-E10
HMS1791M14
HMS1361M14
4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]benzoic acid
HMS3263L13
unii-673m8c29ur
673m8c29ur ,
CCG-205250
HMS2232G03
S4627 ,
4-[(1e)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl]benzoic acid
NCGC00016015-05
NCGC00016015-04
NCGC00016015-06
NCGC00016015-08
NCGC00016015-07
NCGC00016015-02
NCGC00016015-09
LP01176
HY-15682
CS-3253
T3842
SCHEMBL177444
NCGC00261861-01
tox21_501176
FOIVPCKZDPCJJY-JQIJEIRASA-N
p-[(e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid
(e)-4-(2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl)benzoic acid
dtxcid4020743
cas-71441-28-6
NCGC00357251-01
tox21_304044
ttnpb (arotinoid acid)
AC-32901
AKOS024458636
HMS3402M14
mfcd00673917
agn191183
ro 13-7410,agn-191183
sr-01000076154
SR-01000076154-1
SR-01000076154-3
SR-01000076154-5
SW219917-1
A923475
ttnpb(arotinoid acid)
EX-A2171
HMS3675H15
Q27089031
4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthenyl)-1e-propen-1-yl]benzoic acid
HMS3411H15
BRD-K49685476-001-05-0
A13007
SDCCGSBI-0051143.P002
NCGC00016015-18
C76272
WCA44128
CS-0626086
ttnpb (gmp)
HY-15682G

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"4 mg/kg/day, which was equal in toxicity to that of t-RA (1) and 1000-fold less toxic than TTNPB (5)."( Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
Benbrook, DM; Berlin, KD; Birckbichler, PJ; DiSivestro, P; Gale, JB; Hill, DL; Lindamood, C; Lu, S; Madler, MM; Nelson, EC; Patterson, MK; Rowland, TC; Spruce, LW; Subramanian, S; Wang, B; Wang, W; Weerasekare, GM, 1997
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
"Tritiated tetrahydro-tetramethyl-naphthalenyl-propenyl benzoic acid (TTNPB; Ro 13-7410) was administered as a single oral bolus to pregnant hamsters (day 8) to determine the maternal plasma pharmacokinetic profile and peripheral tissue distribution patterns."( Pharmacokinetics, tissue distribution and placental permeability of tetrahydro-tetramethyl-naphthalenyl-propenyl benzoic acid (a retinoidal benzoic acid derivative) in hamsters.
Hatori, A; Howard, WB; Omaye, ST; Sharma, RP; Willhite, CC,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" Thus, betaLG may show benefits in improving the bioavailability of retinoid derivatives."( The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
Heikura, JM; Pohjala, LL; Riihimäki-Lampén, LH; Vahermo, M; Vainio, MJ; Valkonen, KH; Virtanen, VT; Vuorela, PM; Yli-Kauhaluoma, JT, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies using retinoids of diverse structures and potency demonstrated a good correlation between these two events."( Enhancement of gap junctional communication by retinoids correlates with their ability to inhibit neoplastic transformation.
Bertram, JS; Hossain, MZ; Loewenstein, W; Mehta, PP; Wilkens, LR, 1989
)
0.28
" Because the dose-response curves for arotinoids were significantly parallel to that for all-trans-retinoic acid, and because the spectrum of congenital defects induced by arotinoids was identical to that induced by all-trans-retinoic acid and other teratogenic retinoids, the mechanism of embryopathic action of these conformationally restricted retinoids was concluded to be similar to that of all-trans-retinoic acid."( Comparative teratogenic activity of cancer chemopreventive retinoidal benzoic acid congeners (arotinoids).
Ferm, VH; Flanagan, JL; Willhite, CC, 1987
)
0.27
" Using differential dosing schedules, the anti-inflammatory effect of retinoids was clearly distinguished from conventional cyclooxygenase inhibitors."( Anti-inflammatory effects of synthetic retinoids may be related to their immunomodulatory action.
Ball, IJ; Bloxham, DP; Hill, RP; Ney, UM; Westmacott, D, 1987
)
0.27
" Dose-response for gene activation indicated that the potency of TTNPB and tRA in activating mRAR alpha, beta, and gamma was similar after 24 h with comparable EC50s in the nanomolar range."( Multiple factors contribute to the toxicity of the aromatic retinoid TTNPB (Ro 13-7410): interactions with the retinoic acid receptors.
Kauffman, FC; Levin, AA; Pignatello, MA, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
retinoic acid receptor agonistAn agonist that selectively binds to and activates a retinoic acid receptor.
teratogenic agentA role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
retinoidOxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (73)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency25.05940.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency18.54820.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency11.22020.125919.1169125.8920AID2353
Chain A, Ferritin light chainEquus caballus (horse)Potency44.66845.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency23.06010.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency40.79080.007215.758889.3584AID1224835; AID588342
endonuclease IVEscherichia coliPotency10.00000.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency29.26170.100020.879379.4328AID488772; AID488773; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency28.03450.004110.890331.5287AID504466; AID504467
USP1 protein, partialHomo sapiens (human)Potency24.13980.031637.5844354.8130AID504865; AID540327
NFKB1 protein, partialHomo sapiens (human)Potency10.00000.02827.055915.8489AID895; AID928
TDP1 proteinHomo sapiens (human)Potency0.51740.000811.382244.6684AID686978
ThrombopoietinHomo sapiens (human)Potency10.00000.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency36.56590.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency10.59090.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency11.88320.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency39.81070.000214.376460.0339AID588533
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.64990.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.17090.001530.607315,848.9004AID1224819; AID1224820; AID1224841; AID1224848; AID1224849; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency2.81840.375827.485161.6524AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency70.79460.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.00400.000229.305416,493.5996AID1259244; AID1259248
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency44.66840.001024.504861.6448AID588534; AID588535
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency15.84890.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency52.11940.016525.307841.3999AID602332
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.84930.001628.015177.1139AID1259385; AID1259395
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency14.72630.154917.870243.6557AID1346877
Bloom syndrome protein isoform 1Homo sapiens (human)Potency39.81070.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.01260.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency8.19950.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency26.20000.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency5.96220.00255.840031.6228AID899
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency73.84170.010039.53711,122.0200AID588545; AID588547
DNA polymerase betaHomo sapiens (human)Potency35.48130.022421.010289.1251AID485314
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency44.66844.466824.832944.6684AID651749
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency18.49270.65619.452025.1189AID463106
ras-related protein Rab-9AHomo sapiens (human)Potency8.91250.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency0.52120.00378.618923.2809AID2668
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.30600.000627.21521,122.0200AID651741
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency37.93300.425612.059128.1838AID504536
DNA polymerase eta isoform 1Homo sapiens (human)Potency35.48130.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency31.62280.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency9.83440.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency5.63910.004611.374133.4983AID463097; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency37.68580.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency5.62340.125912.234435.4813AID1458
M-phase phosphoprotein 8Homo sapiens (human)Potency0.89130.177824.735279.4328AID488949
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.08910.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency30.30010.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency12.58930.015812.3113615.5000AID1461
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.00210.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency44.66840.002319.595674.0614AID651743
Integrin beta-3Homo sapiens (human)Potency39.81070.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency39.81070.316211.415731.6228AID924
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.00210.001551.739315,848.9004AID1259244
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency14.53751.000010.475628.1838AID1457
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Potency44.66840.015823.527344.6684AID651778
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor alphaHomo sapiens (human)IC50 (µMol)0.03600.00080.93249.0000AID198042
Retinoic acid receptor alphaHomo sapiens (human)Ki0.02100.00100.94856.5000AID200139
Retinoic acid receptor betaHomo sapiens (human)IC50 (µMol)0.00500.00090.43533.0000AID199387
Retinoic acid receptor betaHomo sapiens (human)Ki0.00500.00071.56739.9010AID198222
Retinoic acid receptor gamma Homo sapiens (human)IC50 (µMol)0.02600.00050.01090.0260AID199392
Retinoic acid receptor gamma Homo sapiens (human)Ki0.00500.00001.997510.0000AID198738
Retinoic acid receptor RXR-alphaHomo sapiens (human)IC50 (µMol)1.00000.00600.44502.4000AID199226
Retinoic acid receptor RXR-betaHomo sapiens (human)IC50 (µMol)1.00000.01200.01200.0120AID199362
Retinoic acid receptor RXR-gammaHomo sapiens (human)IC50 (µMol)1.00000.00400.17700.3500AID199380
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Retinoic acid receptor betaHomo sapiens (human)Kd0.00200.00200.00200.0020AID977611
Retinoic acid receptor alphaHomo sapiens (human)EC50 (µMol)0.03400.00020.17902.5119AID1168702; AID166217; AID197922; AID200108
Retinoic acid receptor betaHomo sapiens (human)EC50 (µMol)0.00430.00030.23116.9000AID198201; AID198522; AID199386
Retinoic acid receptor gamma Homo sapiens (human)EC50 (µMol)0.00950.00020.06130.6480AID166227; AID198713; AID199391
Retinoic acid receptor gamma Homo sapiens (human)Kd0.02600.00020.42453.8240AID254257
Retinoic acid receptor RXR-alphaHomo sapiens (human)EC50 (µMol)5.00000.00010.34279.1000AID199222; AID199477
Retinoic acid receptor RXR-betaHomo sapiens (human)EC50 (µMol)10.00000.00080.52545.2000AID199358
Retinoic acid receptor RXR-gammaHomo sapiens (human)EC50 (µMol)10.00000.00010.23801.2250AID199375
Nuclear receptor ROR-gammaHomo sapiens (human)EC50 (µMol)9.00000.02000.70359.0000AID1177731
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ornithine decarboxylaseRattus norvegicus (Norway rat)ID500.00000.00000.00060.0022AID150874
Retinoic acid receptor alphaHomo sapiens (human)AC500.20000.01900.10950.2000AID197905
Retinoic acid receptor betaHomo sapiens (human)AC500.02200.00200.02530.0520AID198360
Retinoic acid receptor gamma Homo sapiens (human)AC500.02600.00300.03230.0680AID7227
Retinoic acid receptor RXR-alphaHomo sapiens (human)AC501.00000.00700.08350.1600AID167587
Cellular retinoic acid-binding protein 1Gallus gallus (chicken)ID500.80000.80001.05001.6000AID52065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (311)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
ureteric bud developmentRetinoic acid receptor alphaHomo sapiens (human)
neural tube closureRetinoic acid receptor alphaHomo sapiens (human)
liver developmentRetinoic acid receptor alphaHomo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor alphaHomo sapiens (human)
growth plate cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
protein phosphorylationRetinoic acid receptor alphaHomo sapiens (human)
germ cell developmentRetinoic acid receptor alphaHomo sapiens (human)
female pregnancyRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of translationRetinoic acid receptor alphaHomo sapiens (human)
hippocampus developmentRetinoic acid receptor alphaHomo sapiens (human)
prostate gland developmentRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of granulocyte differentiationRetinoic acid receptor alphaHomo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor alphaHomo sapiens (human)
regulation of myelinationRetinoic acid receptor alphaHomo sapiens (human)
response to estradiolRetinoic acid receptor alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of type II interferon productionRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of tumor necrosis factor productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-13 productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-4 productionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of interleukin-5 productionRetinoic acid receptor alphaHomo sapiens (human)
response to vitamin ARetinoic acid receptor alphaHomo sapiens (human)
response to cytokineRetinoic acid receptor alphaHomo sapiens (human)
multicellular organism growthRetinoic acid receptor alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
regulation of apoptotic processRetinoic acid receptor alphaHomo sapiens (human)
apoptotic cell clearanceRetinoic acid receptor alphaHomo sapiens (human)
response to ethanolRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of T-helper 2 cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of neuron differentiationRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of cell cycleRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of DNA-templated transcriptionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
regulation of synaptic plasticityRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor alphaHomo sapiens (human)
positive regulation of bindingRetinoic acid receptor alphaHomo sapiens (human)
ventricular cardiac muscle cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
Sertoli cell fate commitmentRetinoic acid receptor alphaHomo sapiens (human)
limb developmentRetinoic acid receptor alphaHomo sapiens (human)
face developmentRetinoic acid receptor alphaHomo sapiens (human)
trachea cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
chondroblast differentiationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of cartilage developmentRetinoic acid receptor alphaHomo sapiens (human)
cellular response to lipopolysaccharideRetinoic acid receptor alphaHomo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor alphaHomo sapiens (human)
cellular response to estrogen stimulusRetinoic acid receptor alphaHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionRetinoic acid receptor alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor alphaHomo sapiens (human)
ureteric bud developmentRetinoic acid receptor betaHomo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor betaHomo sapiens (human)
growth plate cartilage developmentRetinoic acid receptor betaHomo sapiens (human)
apoptotic processRetinoic acid receptor betaHomo sapiens (human)
signal transductionRetinoic acid receptor betaHomo sapiens (human)
striatum developmentRetinoic acid receptor betaHomo sapiens (human)
neurogenesisRetinoic acid receptor betaHomo sapiens (human)
regulation of myelinationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor betaHomo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor betaHomo sapiens (human)
multicellular organism growthRetinoic acid receptor betaHomo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor betaHomo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor betaHomo sapiens (human)
embryonic digestive tract developmentRetinoic acid receptor betaHomo sapiens (human)
ventricular cardiac muscle cell differentiationRetinoic acid receptor betaHomo sapiens (human)
neural precursor cell proliferationRetinoic acid receptor betaHomo sapiens (human)
stem cell proliferationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor betaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor betaHomo sapiens (human)
cell differentiationRetinoic acid receptor betaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
neural tube closureRetinoic acid receptor gamma Homo sapiens (human)
glandular epithelial cell developmentRetinoic acid receptor gamma Homo sapiens (human)
growth plate cartilage chondrocyte growthRetinoic acid receptor gamma Homo sapiens (human)
apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of cell population proliferationRetinoic acid receptor gamma Homo sapiens (human)
regulation of cell sizeRetinoic acid receptor gamma Homo sapiens (human)
anterior/posterior pattern specificationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of gene expressionRetinoic acid receptor gamma Homo sapiens (human)
embryonic camera-type eye developmentRetinoic acid receptor gamma Homo sapiens (human)
regulation of myelinationRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of chondrocyte differentiationRetinoic acid receptor gamma Homo sapiens (human)
response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
embryonic hindlimb morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
multicellular organism growthRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of apoptotic processRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of programmed cell deathRetinoic acid receptor gamma Homo sapiens (human)
regulation of myeloid cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor gamma Homo sapiens (human)
embryonic eye morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
canonical Wnt signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
face developmentRetinoic acid receptor gamma Homo sapiens (human)
trachea cartilage developmentRetinoic acid receptor gamma Homo sapiens (human)
prostate gland epithelium morphogenesisRetinoic acid receptor gamma Homo sapiens (human)
Harderian gland developmentRetinoic acid receptor gamma Homo sapiens (human)
cellular response to retinoic acidRetinoic acid receptor gamma Homo sapiens (human)
stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cellular response to leukemia inhibitory factorRetinoic acid receptor gamma Homo sapiens (human)
negative regulation of stem cell proliferationRetinoic acid receptor gamma Homo sapiens (human)
cell differentiationRetinoic acid receptor gamma Homo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor gamma Homo sapiens (human)
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-betaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-betaHomo sapiens (human)
fatty acid transportCellular retinoic acid-binding protein 1Gallus gallus (chicken)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-gammaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-gammaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (92)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
mRNA regulatory element binding translation repressor activityRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activityRetinoic acid receptor alphaHomo sapiens (human)
transcription coactivator bindingRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor alphaHomo sapiens (human)
chromatin bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor alphaHomo sapiens (human)
signaling receptor bindingRetinoic acid receptor alphaHomo sapiens (human)
protein bindingRetinoic acid receptor alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor alphaHomo sapiens (human)
protein domain specific bindingRetinoic acid receptor alphaHomo sapiens (human)
chromatin DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
histone deacetylase bindingRetinoic acid receptor alphaHomo sapiens (human)
protein kinase B bindingRetinoic acid receptor alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor alphaHomo sapiens (human)
mRNA 5'-UTR bindingRetinoic acid receptor alphaHomo sapiens (human)
protein kinase A bindingRetinoic acid receptor alphaHomo sapiens (human)
alpha-actinin bindingRetinoic acid receptor alphaHomo sapiens (human)
heterocyclic compound bindingRetinoic acid receptor alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor betaHomo sapiens (human)
DNA bindingRetinoic acid receptor betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor betaHomo sapiens (human)
protein-containing complex bindingRetinoic acid receptor betaHomo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor betaHomo sapiens (human)
heterocyclic compound bindingRetinoic acid receptor betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor betaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor gamma Homo sapiens (human)
DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
chromatin bindingRetinoic acid receptor gamma Homo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor gamma Homo sapiens (human)
protein bindingRetinoic acid receptor gamma Homo sapiens (human)
zinc ion bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear retinoid X receptor bindingRetinoic acid receptor gamma Homo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
nuclear receptor activityRetinoic acid receptor gamma Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor gamma Homo sapiens (human)
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid bindingCellular retinoic acid-binding protein 1Gallus gallus (chicken)
retinoid bindingCellular retinoic acid-binding protein 1Gallus gallus (chicken)
retinal bindingCellular retinoic acid-binding protein 1Gallus gallus (chicken)
retinol bindingCellular retinoic acid-binding protein 1Gallus gallus (chicken)
fatty acid bindingCellular retinoic acid-binding protein 1Gallus gallus (chicken)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
molecular condensate scaffold activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (54)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
nucleusRetinoic acid receptor alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor alphaHomo sapiens (human)
nucleolusRetinoic acid receptor alphaHomo sapiens (human)
cytoplasmRetinoic acid receptor alphaHomo sapiens (human)
cytosolRetinoic acid receptor alphaHomo sapiens (human)
plasma membraneRetinoic acid receptor alphaHomo sapiens (human)
actin cytoskeletonRetinoic acid receptor alphaHomo sapiens (human)
dendriteRetinoic acid receptor alphaHomo sapiens (human)
perinuclear region of cytoplasmRetinoic acid receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor alphaHomo sapiens (human)
chromatinRetinoic acid receptor alphaHomo sapiens (human)
protein-containing complexRetinoic acid receptor alphaHomo sapiens (human)
nucleusRetinoic acid receptor alphaHomo sapiens (human)
nucleusRetinoic acid receptor betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor betaHomo sapiens (human)
cytoplasmRetinoic acid receptor betaHomo sapiens (human)
chromatinRetinoic acid receptor betaHomo sapiens (human)
nucleusRetinoic acid receptor betaHomo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
nucleoplasmRetinoic acid receptor gamma Homo sapiens (human)
cytoplasmRetinoic acid receptor gamma Homo sapiens (human)
membraneRetinoic acid receptor gamma Homo sapiens (human)
chromatinRetinoic acid receptor gamma Homo sapiens (human)
transcription regulator complexRetinoic acid receptor gamma Homo sapiens (human)
nucleusRetinoic acid receptor gamma Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleusRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleolusRetinoic acid receptor RXR-betaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-betaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-betaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-betaHomo sapiens (human)
cytosolCellular retinoic acid-binding protein 1Gallus gallus (chicken)
axonCellular retinoic acid-binding protein 1Gallus gallus (chicken)
neuron projectionCellular retinoic acid-binding protein 1Gallus gallus (chicken)
cell body fiberCellular retinoic acid-binding protein 1Gallus gallus (chicken)
nucleusCellular retinoic acid-binding protein 1Gallus gallus (chicken)
cytosolCellular retinoic acid-binding protein 1Gallus gallus (chicken)
nucleoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
cytoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (269)

Assay IDTitleYearJournalArticle
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347171Orthogonal mCherry assay for qRT-PCR qHTS of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID52069Inhibition of binding of [3H]all-trans-retinoic acid to cellular retinoic acid binding protein at 3 uM compound concentration, in rat1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID200398Growth inhibition of Cloudman S91 Melanoma cells at 1 uM drug concentration.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Affinity therapeutics. 1. Selective incorporation of 2-thiouracil derivatives in murine melanomas. Cytostatic activity of 2-thiouracil arotinoids, 2-thiouracil retinoids, arotinoids, and retinoids.
AID445393Solubility assessed as aggregate formation at >= pH 5 by dynamic light scattering method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID107645Effect of compound on right testicle to body weight ratios in mice at 0.4 mg/kg/day dose on day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID209487Percent survivors at dose 1.0 umol/kg day1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID110516Enlarged lymph in gross pathological observations with hypervitaminosis A in mice at 0.8 mg/kg/day dose with gross observations/total number of animals in group; 8/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID84854Molarity required to effect reversal of keratinization in 50% of cultures.1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID168957Average number of fractures per rat at 0.05 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID110512Enlarged lymph in gross pathological observations with hypervitaminosis A in mice at 0.01 mg/kg/day dose with gross observations/total number of animals in group; 6/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID110529Enlarged spleen in Gross pathological observations with hypervitaminosis A in mice at 0.4 mg/kg/day dose with gross observations/total number of animals in group; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID167587Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RXR-alpha2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID1154939Agonist activity at Gal4-fused human RXR-beta transfected in human HeLa cells at 875 nM after 12 hrs by luciferase reporter gene assay relative to control2014ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5
Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold.
AID107122Avoiding pressure on limbs at 0.4 mg/kg/day dose in mice with hypervitaminosis; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID107623Effect of compound on Spleen to body weight ratios in mice at 0.8 mg/kg/day dose on day 65; dead by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID107106Approximate day to determine 10% weight loss in mice at 0.05 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID199392Binding affinity against retinoic Acid gamma receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID7227Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID1168702Agonist activity at human RARalpha expressed in HEK293 cells by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
AID80939The ability to induce differentiation of HL-60 cells relative to that of retinoic acid1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids.
AID168961Average number of fractures per rat at 0.8 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID44158Tested for toxicity against C3H10T1/2 cell line of murine embryo fibroblasts at 10e-8 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID107641Effect of compound on right testicle to body weight ratios in mice at 0.01 mg/kg/day dose on day 251997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID107620Effect of compound on Spleen to body weight ratios in mice at 0.1 mg/kg/day dose on day 65; dead by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID114618Inhibition of tumor-promoter-induced ornithine decarboxylase in TPA-treated female hairless mice1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID44148Tested for anticancer activity by measuring the number of communicating cells using gap junctional communication assay at 10e-6 M (P>0.001)1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID115325Calculated 30-day maximally tolerated dose based on 10% weight loss in mice at 0.01 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID198042Binding affinity against retinoic Acid alpha receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID168851Fracture incidents in rat at 0.05 mg/kg/day; 7/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID128379Tested for relative activity in a 20-week anti-papilloma experiment in female CD-1 mice at dose 170 nmol;d- Animals died at 1-2 weeks1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID199375Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID110513Enlarged lymph in gross pathological observations with hypervitaminosis A in mice at 0.05 mg/kg/day dose with gross observations/total number of animals in group; 8/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID44163Toxicity against C3H10T1/2 cell line of murine embryo fibroblasts at 10e-10 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID110515Enlarged lymph in gross pathological observations with hypervitaminosis A in mice at 0.4 mg/kg/day dose with gross observations/total number of animals in group; 12/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID199362Binding affinity against retinoic Acid X beta receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID209341Mortality range in days at dose 20 umol/kg day; 6-81984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID107630Effect of compound on adrenal to body weight ratios in mice at 0.01 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID107118Avoiding pressure on limbs at 0.01 mg/kg/day dose in mice hypervitaminosis; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID110514Enlarged lymph in gross pathological observations with hypervitaminosis A in mice at 0.2 mg/kg/day dose with gross observations/total number of animals in group; 16/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID13309Tested for experimental arotinoid inhibitory dose1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Modeling the anticarcinogenic action of retinoids by making use of the OASIS method. 3. Inhibition of the induction of ornithine decarboxylase by arotinoids.
AID212170Mortality rate in mice at 0.05 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID110383Effects of retinoids on thymus to body weight ratios in mice at 0.01 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID128377Tested for relative activity in a 20-week anti-papilloma experiment in female CD-1 mice at dose 1.7 nmol1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID107631Effect of compound on adrenal to body weight ratios in mice at 0.05 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID1808019Inhibition of SARS CoV2 C-terminal His6-tagged 3CL protease (3264 to 3569 residues) expressed in Escherichia coli BL21 DE3 using rr-K(MCA)-ATLQAIAS-K(DNP)-COOH preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 0.02021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID83835Activity of compound the was expressed as ratio of active hamster tracheal organ cultures(TOC) to the total cultures at 10e-11 M concentration; 15/151984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID166117Percentage inhibition of cholesterol-3-sulfate activity in rabbit at 0.1 nM.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID107619Effect of compound on Spleen to body weight ratios in mice at 0.05 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID111342Skin scaling at 0.8 mg/kg/day in mice with hypervitaminosis; 12/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID209489Percent survivors at dose 10 umol/kg day1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID113773Compound was tested for its effect on body weight gain in mice at a dose of 3.6 nmol/25 g1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
A new class of potent RAR antagonists: dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids.
AID198201Transcriptional activation of Retinoic acid receptor RAR beta1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID150874Inhibitory effect of compound on the induction of ornithine decarboxylase in CD-1 mouse.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID110528Enlarged spleen in Gross pathological observations with hypervitaminosis A in mice at 0.1 mg/kg/day dose with gross observations/total number of animals in group; 4/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID111338Skin scaling at 0.05 mg/kg/day in mice with hypervitaminosis; 8/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID44154Inhibition of neoplastic transformation at a concentration of 10e-8 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID199358Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID209483Percent survivors at dose 30 umol/kg day1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID107121Avoiding pressure on limbs at 0.2 mg/kg/day dose in mice with hypervitaminosis; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID109752Total dose of 10% weight loss in mice at 0.01 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID107642Effect of compound on right testicle to body weight ratios in mice at 0.05 mg/kg/day dose on day 25; dead on day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID150720Inhibition of the induction of ornithine decarboxylase in mouse epidermis by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (ODC) at dose 17 nmol*-p<0.0011984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID254266Dissociation constant for Retinoid X receptor alpha; NAA = Not an active agonist2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Ligand recognition by RAR and RXR receptors: binding and selectivity.
AID210769Inhibitory dose against tracheal organ culture reversal of keratinization1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID129746Percent decrease in average number of papillomas 0.17 at dose*-p<0.0011984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID109016Alopecia observed at 0.4 mg/kg/day dose in mice with hypervitaminosis; 8/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID209493Percent survivors at dose 30 umol/kg day1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID198360Transcriptional activation in CV-1 cells expressing Retinoic acid receptor beta2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID109753Total dose of 10% weight loss in mice at 0.05 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID108888Alopecia observed at 0.05 mg/kg/day dose in mice with hypervitaminosis; 8/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID111341Skin scaling at 0.4 mg/kg/day in mice with hypervitaminosis; 15/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID107120Avoiding pressure on limbs at 0.1 mg/kg/day dose in mice hypervitaminosis; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID44153Inhibition of neoplastic transformation at a concentration of 10e-6 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID199064Percent activation of Retinoic acid receptor gamma receptor at 1 uM relative to 1 uM trans-retinoic acid2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID166227Effective concentration against RAR-gamma receptor1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID82828Induction of transglutaminase (TGase) activity in HL-60 cells1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID44157Tested for toxicity against C3H10T1/2 cell line of murine embryo fibroblasts at 10e-6 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID212172Mortality rate in mice at 0.2 mg/kg/day; range (8-19)1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID209479Percent survivors at dose 10 umol/kg day1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID68777In vitro promotion of plasminogen activator secretion from F9 (murine teratocarcinoma) cells.1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID107635Effect of compound on adrenal to body weight ratios in mice at 0.8 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID199380Binding affinity against retinoic Acid X gamma receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID1154940Agonist activity at Gal4-fused human RXR-beta transfected in human HeLa cells at 541 nM after 12 hrs by luciferase reporter gene assay relative to control2014ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5
Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold.
AID199222Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID110517Enlarged spleen in Enlarged spleen in Gross pathological observations with hypervitaminosis A in mice at 0.2 mg/kg/day dose with gross observations/total number of animals in group; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID107123Avoiding pressure on limbs at 0.8 mg/kg/day dose in mice hypervitaminosis; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID250241Ability to induce maturation and cell death of NB4 cells labelled with V-FITC on day 32004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID107632Effect of compound on adrenal to body weight ratios in mice at 0.1 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID107644Effect of compound on right testicle to body weight ratios in mice at 0.1 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID80929The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids.
AID168960Average number of fractures per rat at 0.4 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID1154937Agonist activity at Gal4-fused human RXR-beta transfected in human HeLa cells at 51 nM after 12 hrs by luciferase reporter gene assay relative to control2014ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5
Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold.
AID107643Effect of compound on right testicle to body weight ratios in mice at 0.05 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID390534Agonist activity at human RARbeta expressed in human HeLa cells assessed as relative luminescence units at >=10 uM by luciferase assay relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
New retinoid chemotypes: 9-cis-retinoic acid analogs with hydrophobic rings derived from terpenes as selective RAR agonists.
AID445390Binding affinity to bovine beta-lactoglobulins assessed as aggregate diameter size formed at 200 uM by dynamic light scattering method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID110384Effects of retinoids on thymus to body weight ratios in mice at 0.05 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID209481Percent survivors at dose 3.3 umol/kg day1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID110527Enlarged spleen in Gross pathological observations with hypervitaminosis A at 0.8 mg/kg/day dose with gross observations/total number of animals in group; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID124528Compound was tested for cutaneous toxicity score in mice at a dose of 3.6 nmol/25 g1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
A new class of potent RAR antagonists: dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids.
AID212171Mortality rate in mice at 0.1 mg/kg/day; range (12-24)1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID110361Effect of compound on thymus to body weight ratios in mice at 0.1 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID198222Binding affinity to retinoic acid receptor beta using [3H]CD 367 as radioligand1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID445389Solubility assessed as lowest drug level in which detectable aggregates formed by dynamic light scattering method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID168853Fracture incidents in rat at 0.2 mg/kg/day; 3/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID52065Concentration of compound required to inhibit binding of 2.5 uM [3H]all-trans-retinoic acid by 50% in chick1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID210789Percentage inhibition of Transglutaminase activity in rabbit at 10 nM.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID111340Skin scaling at 0.2 mg/kg/day in mice with hypervitaminosis; 14/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID82977In vitro apoptotic activity against HL60 cells after 48 hr of treatment.2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Programmed cell death (PCD) associated with the stilbene motif of arotinoids: discovery of novel apoptosis inducer agents possessing activity on multidrug resistant tumor cells.
AID107105Approximate day to determine 10% weight loss in mice at 0.01 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID108887Alopecia observed at 0.01 mg/kg/day dose in mice with hypervitaminosis; 6/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID209491Percent survivors at dose 3.3 umol/kg day1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID445386Binding affinity to reindeer beta-lactoglobulin by fluorescence spectroscopy2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID390535Agonist activity at human RARgamma expressed in human HeLa cells assessed as relative luminescence units at >=10 uM by luciferase assay relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
New retinoid chemotypes: 9-cis-retinoic acid analogs with hydrophobic rings derived from terpenes as selective RAR agonists.
AID128376Tested for relative activity in a 20-week anti-papilloma experiment in female CD-1 mice at dose 0.17 nmol1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID107646Effect of compound on right testicle to body weight ratios in mice at 0.4 mg/kg/day dose on day 65; dead on day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID250165Evaluated for mean value of the fluorescence intensity of CD11c-PE expressing NB4 cells at day 62004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID250164Evaluated for mean value of the fluorescence intensity of CD11c-PE expressing NB4 cells at day 32004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID132681Inhibition of Chondrogenesis in day 11 embryonic limb bud cells1996Journal of medicinal chemistry, Aug-30, Volume: 39, Issue:18
Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
AID168850Fracture incidents in rat at 0.01 mg/kg/day; 1/71997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID212173Mortality rate in mice at 0.4 mg/kg/day; range (8-19)1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID199391Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID110362Effect of compound on thymus to body weight ratios in mice at 0.2 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID44169Tested for inhibition of neoplastic transformation by measuring the transformed foci per dish at 10e-8 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID168852Fracture incidents in rat at 0.1 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID198373Retinoid activity at 10 e-5 M (E)-RA against Retinoic acid receptor beta for gene transcriptional activation in transfected CV-1 cells1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID107633Effect of compound on adrenal to body weight ratios in mice at 0.2 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID168855Fracture incidents in rat at 0.8 mg/kg/day; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID150731TInhibition of the induction of ornithine decarboxylase in mouse epidermis by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (ODC) at dose 1.7 nmol*-p<0.0011984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID110364Effect of compound on thymus to body weight ratios in mice at 0.8 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID166118Percentage inhibition of cholesterol-3-sulfate activity rabbit at 10 nM.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID212169Mortality rate in mice at 0.01 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID44165Inhibition of neoplastic transformation was measured by measuring the transformed foci per dish at 10e-6 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID166122cross-linked envelope inhibition assay was performed at 10 nM compound concentration1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID44160The compound was tested for inhibition of Neoplastic transformation, at a concentration of 10e-10 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID83976Activity of compound the was expressed as ratio of active hamster tracheal organ cultures(TOC) to the total cultures at 10e-12 M concentration; 6/151984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID115326Calculated 30-day maximally tolerated dose based on 10% weight loss in mice at 0.05 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID197905Transcriptional activation in CV-1 cells expressing Retinoic acid receptor alpha2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID200108Transcriptional activation of Retinoic acid receptor RAR alpha1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID168956Average number of fractures per rat at 0.01 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID168959Average number of fractures per rat at 0.2 mg/kg/day; 1/31997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID390533Agonist activity at human RARalpha expressed in human HeLa cells assessed as relative luminescence units at >=10 uM by luciferase assay relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
New retinoid chemotypes: 9-cis-retinoic acid analogs with hydrophobic rings derived from terpenes as selective RAR agonists.
AID168854Fracture incidents in rat at 0.4 mg/kg/day; 3/121997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID107119Avoiding pressure on limbs at 0.05 mg/kg/day dose in mice with hypervitaminosis; 0/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID209351Percent survivors at dose 1.0 umol/kg day1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID83822Activity of compound the was expressed as ratio of active hamster tracheal organ cultures(TOC) to the total cultures at 10e-10 M concentration; 15/151984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID110526Enlarged spleen in Gross pathological observations with hypervitaminosis A at 0.01 mg/kg/day dose with gross observations/total number of animals in group; 5/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID107618Effect of compound on Spleen to body weight ratios in mice at 0.01 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID199477Transcriptional activation of Retinoid X receptor RXR alpha1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID167596Retinoid activity at 10 e-5 M (9Z)- RA against RXR-alpha receptor for gene transcriptional activation in transfected CV-1 cells1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID109017Alopecia observed at 0.8 mg/kg/day dose in mice with hypervitaminosis; 3/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID445391Solubility in DMSO assessed as aggregate diameter size at 200 uM by dynamic light scattering method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID197922Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID212174Mortality rate in mice at 0.8 mg/kg/day; range (7-8)1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID198738Binding affinity to retinoic acid receptor (RAR) gamma using [3H]CD 367 as radioligand1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID68787Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID108711Compound was tested for abrasion score in mice at a dose of 3.6 nmol/25 g1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
A new class of potent RAR antagonists: dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids.
AID166226Retinoid activity at 10 e-5 M (E)-RA against RAR-gamma receptor for gene transcriptional activation in transfected CV-1 cells1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID200139Binding affinity to retinoic acid receptor alpha using [3H]CD 367 as radioligand1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes.
AID107622Effect of compound on Spleen to body weight ratios in mice at 0.4 mg/kg/day dose on day 65; dead by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID167591Percent activation of Retinoic acid receptor RXR-alpha at 1 uM relative to 1 uM 9-cis-retinoic acid2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID198553Percent activation of Retinoic acid receptor beta at 1 uM relative to 1 uM trans-retinoic acid2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID107621Effect of compound on Spleen to body weight ratios in mice at 0.2 mg/kg/day dose on day 65; dead by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID200399Growth inhibition of Cloudman S91 Melanoma cells at 10 uM drug concentration.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Affinity therapeutics. 1. Selective incorporation of 2-thiouracil derivatives in murine melanomas. Cytostatic activity of 2-thiouracil arotinoids, 2-thiouracil retinoids, arotinoids, and retinoids.
AID1154938Agonist activity at Gal4-fused human RXR-beta transfected in human HeLa cells at 125 nM after 12 hrs by luciferase reporter gene assay relative to control2014ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5
Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold.
AID68786Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.
AID139988In vitro inhibition of chondrogenesis in mouse embryo limb bud cells1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID254257Dissociation constant for Retinoic acid receptor gamma2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Ligand recognition by RAR and RXR receptors: binding and selectivity.
AID81281Transglutaminase activity in HL-60 cdm-1 cells1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID198522Effective concentration against Retinoic acid receptor beta1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID111337Skin scaling at 0.01 mg/kg/day in mice with hypervitaminosis; 4/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID250242Ability to induce maturation and cell death of NB4 cells labelled with V-FITC on day 62004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Structure-activity relationships of methylene or terminal side chain modified retinoids on the differentiation and cell death signaling in NB4 promyelocytic leukemia cells.
AID82984In vitro cytotoxicity against HL60 cells.2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Programmed cell death (PCD) associated with the stilbene motif of arotinoids: discovery of novel apoptosis inducer agents possessing activity on multidrug resistant tumor cells.
AID445387Binding affinity to bovine beta-lactoglobulins at 100 uM by ultrafiltration/HPLC method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID110511Enlarged lymph in gross pathological observations with hypervitaminosis A at 0.1 mg/kg/day dose with gross observations/total number of animals in group'' 16/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID209346Mortality range in days at dose 30 umol/kg day; 7-101984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID199226Binding affinity against retinoic Acid X alpha receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID129747Percent decrease in average number of papillomas 1.7 at dose*-p<0.0011984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID209345Mortality range in days at dose 30 umol/kg day; 10-151984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID198713Transcriptional activation of Retinoic acid receptor RAR gamma1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
AID166216Retinoid activity at 10 e-5 M (E)-RA against RAR-alpha receptor for gene transcriptional activation in transfected CV-1 cells1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID44146Tested for anticancer activity by measuring the number of communicating cells using gap junctional communication assay at 10*e-6 M (P>0.001)1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID209347Mortality range in days at dose 30 umol/kg day; 7-111984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID1808025Inhibition of SARS-Cov2 N-terminal full-length MBP-tagged 3CL protease expressed in Escherichia coli using DABCYL-KTSAVLQSGFRKME-EDANS as substrate preincubated for 30 mins followed by substrate addition and measured after 3 hrs by fluorescence assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID168958Average number of fractures per rat at 0.1 mg/kg/day1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID199387Binding affinity against retinoic Acid beta receptor using [3H]- -9-cis-Retinoic Acid in competitive binding assay1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID128381Tested for relative activity in a 20-week anti-papilloma experiment in female CD-1 mice at dose 17 nmol; e-Animalsdied at 3-7 weeks1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Conformationally restricted retinoids.
AID107634Effect of compound on adrenal to body weight ratios in mice at 0.4 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID113567Compound was tested for flaking score in mice at a dose of 3.6 nmol/25 g1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
A new class of potent RAR antagonists: dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids.
AID44168Tested for inhibition of neoplastic transformation by measuring the transformed foci per dish at 10e-10 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID109015Alopecia observed at 0.2 mg/kg/day dose with hypervitaminosis; 10/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID166217Effective concentration against RAR-alpha receptor1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity.
AID199386Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Synthesis of high specific activity [3H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties.
AID445388Binding affinity to reindeer beta-lactoglobulin at 100 uM by ultrafiltration/HPLC method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID420836Inhibition of Dictyostelium discoideum AX2 RNase P by double reciprocal plot2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity.
AID44161The compound was tested for inhibition of neoplastic transformation, at a concentration of 10e-10 M1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity.
AID1177731Inverse agonist activity at human RoRc-LBD fusion protein with GST expressed in BL-21 (BL3) cells assessed as SRC1 coactivator peptide recruitment2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc).
AID445385Binding affinity to bovine beta-lactoglobulins by fluorescence spectroscopy2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The binding of synthetic retinoids to lipocalin beta-lactoglobulins.
AID198064Percent activation of Retinoic acid receptor alpha at 1 uM relative to 1 uM trans-retinoic acid2000Bioorganic & medicinal chemistry letters, Jun-19, Volume: 10, Issue:12
4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor alpha agonists.
AID110530Enlarged spleen in gross pathological observations with hypervitaminosis A at 0.05 mg/kg/day dose with gross observations/total number of animals in group; 5/81997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID110363Effect of compound on thymus to body weight ratios in mice at 0.4 mg/kg/day dose; all the animals died by day 651997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID111339Skin scaling at 0.1 mg/kg/day in mice with hypervitaminosis; 14/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID108889Alopecia observed at 0.1 mg/kg/day dose in mice with hypervitaminosis; 10/161997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346788Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)2000Journal of molecular biology, Sep-08, Volume: 302, Issue:1
Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
AID1346786Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)1995Molecular and cellular biology, Jul, Volume: 15, Issue:7
Activation of retinoid X receptors induces apoptosis in HL-60 cell lines.
AID1346786Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)1994Molecular and cellular biology, Jan, Volume: 14, Issue:1
Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping.
AID1346786Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)2000Current pharmaceutical design, Jan, Volume: 6, Issue:1
Therapeutic applications for ligands of retinoid receptors.
AID1346740Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)2000Current pharmaceutical design, Jan, Volume: 6, Issue:1
Therapeutic applications for ligands of retinoid receptors.
AID1346788Human Retinoic acid receptor-gamma (1B. Retinoic acid receptors)1994Molecular and cellular biology, Jan, Volume: 14, Issue:1
Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping.
AID1346740Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)2000Journal of molecular biology, Sep-08, Volume: 302, Issue:1
Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
AID1346740Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)1995Molecular and cellular biology, Jul, Volume: 15, Issue:7
Activation of retinoid X receptors induces apoptosis in HL-60 cell lines.
AID1346740Human Retinoic acid receptor-alpha (1B. Retinoic acid receptors)1994Molecular and cellular biology, Jan, Volume: 14, Issue:1
Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping.
AID1346786Human Retinoic acid receptor-beta (1B. Retinoic acid receptors)2000Journal of molecular biology, Sep-08, Volume: 302, Issue:1
Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1811Experimentally measured binding affinity data derived from PDB2004EMBO reports, Sep, Volume: 5, Issue:9
Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004EMBO reports, Sep, Volume: 5, Issue:9
Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (169)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (14.79)18.7374
1990's51 (30.18)18.2507
2000's53 (31.36)29.6817
2010's30 (17.75)24.3611
2020's10 (5.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.47 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.15%)5.53%
Reviews4 (2.30%)6.00%
Case Studies1 (0.57%)4.05%
Observational0 (0.00%)0.25%
Other167 (95.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]